Liver Cancer Drug Market To Triple By 2014; MNCs Will Take Lead
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Sales of hepatocellular carcinoma drugs in China will nearly triple from $53 million in 2009 to $144 million in 2014, a new research report from Decision Resources found